Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

Abbott Laboratories is a well-diversified health care company, with four distinct units: medical devices, diagnostics, ...

Abbott Laboratories (NYSE: ABT) is a well-diversified health care company, with four distinct units: medical devices, ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes Care and Medical Devices.

Abbott has received an innovation award for Lingo, its first consumer biowearable over-the-counter device designed to support improvements in overall health and wellness.

Sensor integration with Abbott’s FreeStyle Libre 2 Plus and Dexcom ... the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with ...

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

Abbott has won an innovation award for Lingo, its first consumer biowearable over-the-counter device to empower people in improving overall health and wellness.